Kancera strengthens its patent portfolio in cancer metabolism
11 January 2012
Stockholm, Sweden. Kancera has registered a patent application
for novel compounds targeting the energy metabolism of cancer.
The new patent application covers a strategy to facilitate the
uptake of substances in cancer cells. These synthetic molecules
weaken the tumour by inhibiting the energy metabolism of cancer
cells, thereby breaking the tumour resistance to radiation and
chemotherapy, without harming healthy cells.
Kancera has been invited to present the project at the World
Cancer Metabolism Summit, February 2012, in Washington, USA.
Kancera has previously reported that active substances against
cancer energy metabolism significantly increase the sensitivity of
cells derived from gastric cancer to cis-platin, a clinically proven
chemotherapy that are widely used in the treatment of cancer.
Kancera has during June and September 2011 registered two
international patent applications (PCT/EP2011/060526 and
PCT/EP2011/066250). The new patent application covers an additional
new compound class of small synthetic molecules.
About the PFKFB3 project
Blocking the mechanisms that enable cancer cells to overcome
periods of hypoxia (oxygen defiency), may pave the way for new
treatment strategies. The project is based on a specific inhibition
of the enzyme PFKFB3 resulting in decreased metabolism and cell
growth in hypoxic cancer environments.
Inhibition of PFKFB3 is expected to starve and weaken the tumour
cells by reducing its glycolysis and cell division. In this way one
can overcome the current problems with tumour resistance to
radiation and chemotherapy.